Sheehan's Syndrome Case Studies

The individuals discussed in the present case, Thomas and Jill Henderson, represent a married couple who have been experiencing difficulty becoming pregnant. Specifically, Thomas has a low sperm count and motility, whereas Jill has irregular ovulation. The couples’ health insurance plan, Clarion, denied coverage of an infertility treatment, Protocol I, because it concluded that the Hendersons’ condition did not constitute an illness.

There’s no easy way to put this, so I’ll say it straight out. It’s time I faced up to the truth. I’m fourteen years old and I have Ishmael Leseur’s Syndrome. There is no cure. But, as it turns out, Ishmael Leseur’s Syndrome is the best thing that ever happened to me.

denied by Humana. This was our first attempt to purchase this medication since our group (HM

Assist the patent and family, as appropriate, in coming to a consensus regarding the options that best meet the patient’s goal for care.

The proposed Right-to-Try bill requires the federal government to allow for unrestricted access to investigational drugs, biological products, or devices to patients who are considered to have been diagnosed with a life-threatening illness when prescribed by a physician. The proposed law stipulates that the patient must have exhausted all other treatment options, and the investigational drug must have completed a

The fear of medical malpractice lawsuits is an issue faced by all who practice medicine. To avoid public criticism by colleagues or the public from their profession and sometimes lose their ability to practice, physicians, and doctors feel forced to follow published standards of care. These treatments often include prescribing medications made to treat

All three providers have agreed that prescribing a pharmacologic and non-pharmacologic treatment regimen must result from clinical judgment based on a thorough assessment of the patient and the patient’s environment, present and past medical history, current home medication, the determination of differential diagnosis and appropriate diagnostic procedure, a review of potential alternative therapies and specific knowledge about the drug chosen and the disease process it is designed to treat (Woo & Robinson, 2016; p.6).

The carrier’s decision in denying coverage for the requested prescription Harvoni was not appropriate for the treatment of this member’s condition. This member meets criteria for treatment as recommended by the AASLD, the duration is limited and the treatment is expected to be effective for this member. The requested prescription Harvoni is medically necessary for the treatment of this member’s condition. The previous denial is

Susan started taking these medications approximately thirteen years ago, a couple years after she divorced her husband. While married she had an extremely unhealthy relationship with her husband and his family and she basically did slave labor for his family’s carpet cleaning business for ten years. Shortly after the divorce her ex-husband remarried a woman who made Susan and Hannah’s life miserable. The new wife constantly threatened to take Susan to court to get custody of Hannah. She was verbally abusive to Susan including calling her a

The Plaintiff (Rector) likely has a strong argument that she should survive summary judgment because there is a question of material fact on product identification. Courts have consistently held that a brand name drug manufacturer cannot be held liable for injuries caused by a generic form of the drug they produce. In re Darvocet, Darvon, and Propoxyphene Products Liability Litig., 756 F.3d 917, 940 (6th Cir. 2014). However, if plaintiffs claim they took the brand name drug itself, then courts have tended to apply a low standard for product identification.

This 72-year-old claimant sustained a work-related injury on 04/22/07. The claimant continues to have discomfort in the right thigh, buttock area, and lumbar spine. She has a pain rating of 2-7/10. She takes Voltaren more regularly and the Tylenol only when the pain is greater. It was noted that she has been taking these medications for years with benefit. The claimant’s pain has decreased and the claimant is able to complete activities of daily living with the use of medications. However, this medication is listed as a “Non-Preferred” drug in the formulary. There is no documentation of failed trials of “Preferred” drugs and documentation indicating that this medication is more beneficial to the claimant than a “Non-Preferred”

Good morning all, the problems with HPN, Optum and BriovaRX continue doses are still being rejected by the plan if they are not under the 0.03mg/kg criteria. BriovaRX is having problems getting the scripts transfer over from optum, they are also having problems verifying authorizations that are already in place because they keep asking optum rather than the plan. At this point I don't think a lunch is necessary since none of the problems have been resolved and no one has been able to get a hold of someone at HPN/SHL to solve the dosing problem. The most reasonable solution at this point is to switch patients to alternative medications and for those that we cant switch. patients have been given information on other insurance plans they can use

Alexis had requested several times additional time for quizzes for Journalism 362. Instructor Espin stated several times " I don't think you need any additional time you are doing well on the quizzes"

Also, the Rights theory is appropriate in this case, because one might argue that basic human rights are involved. Merck might be responsible to do research with ivermectin if it’s decided that some basic right is being broken.

The pharmaceutical industry confronts several dilemmas every year. Most of these dilemmas revolve around money or whether or not to sacrifice now for a bigger payoff in the end concerning money and/or lives. Pharmaceutical companies tend to use shortcuts that create ethical problems. Drug companies have spent millions/billions of dollars in research, and they obviously want to see